Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 63,566 shares of the biopharmaceutical company’s stock after selling 7,260 shares during the period. Hantz Financial Services Inc.’s holdings in Gilead Sciences were worth $5,872,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GILD. Algert Global LLC acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $254,000. Creative Planning increased its stake in Gilead Sciences by 8.4% in the second quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company’s stock valued at $12,939,000 after purchasing an additional 14,544 shares during the period. Quarry LP acquired a new position in Gilead Sciences in the second quarter valued at $43,000. B. Riley Wealth Advisors Inc. increased its stake in Gilead Sciences by 25.1% in the second quarter. B. Riley Wealth Advisors Inc. now owns 35,674 shares of the biopharmaceutical company’s stock valued at $2,448,000 after purchasing an additional 7,155 shares during the period. Finally, SPC Financial Inc. increased its stake in Gilead Sciences by 18.2% in the second quarter. SPC Financial Inc. now owns 4,980 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 768 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 1.9 %

Shares of Gilead Sciences stock opened at $95.59 on Thursday. The business has a 50-day moving average of $92.00 and a 200-day moving average of $85.44. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $119.13 billion, a PE ratio of 1,062.11, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm earned $2.29 earnings per share. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GILD. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Truist Financial boosted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Wolfe Research began coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Finally, Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 456,234 shares of company stock valued at $42,130,461. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.